VYNE Therapeutics Inc. (VYNE)
USD 2.42
(-8.33%)
USD 2.42
(-8.33%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.34 Million | -29.2 Million | -56.36 Million | -137.08 Million | -65.1 Million | -52.73 Million |
| Net Income | -27.87 Million | -23.21 Million | -73.32 Million | -255.56 Million | -73.7 Million | -51.44 Million |
| Depreciation & Amortization | -255 Thousand | 72 Thousand | 109 Thousand | 341 Thousand | 700 Thousand | 22 Thousand |
| Deferred income taxes | -3.2 Million | - | 1.52 Million | 56.3 Million | - | - |
| Stock-based compensation | 3.3 Million | 4.29 Million | 8.08 Million | 18.1 Million | 6.7 Million | 3.63 Million |
| Change in working capital | 60 Thousand | 2.27 Million | 4.77 Million | -40.33 Million | 1.89 Million | -4.17 Million |
| Other non-cash items | 2.62 Million | -12.63 Million | 2.47 Million | 84.07 Million | -691 Thousand | -774 Thousand |
| Investing Cash Flow | -57.35 Million | 15.66 Million | 1.02 Million | 89.1 Million | 41.37 Million | -33.87 Million |
| Investments in PPE | - | - | - | -113 Thousand | -11 Thousand | -140 Thousand |
| Acquisitions | 5 Million | 15.66 Million | - | 38.64 Million | 40 Thousand | - |
| Investment purchases | -62.35 Million | - | - | -38.64 Million | -83.39 Million | -126.7 Million |
| Sales/Maturities of investments | - | - | 1.02 Million | 50.57 Million | 124.78 Million | 92.96 Million |
| Other Investing Activities | 5 Million | 15.66 Million | - | 38.64 Million | -40 Thousand | - |
| Financing Cash Flow | 82.39 Million | 1.65 Million | 39.77 Million | 61.8 Million | 4.99 Million | 125.91 Million |
| Debt repayment | - | - | -36.43 Million | - | -33.9 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -360 Thousand | - | -294 Thousand | -141 Thousand | -32 Thousand | - |
| Common Stock Issuance | 82.75 Million | 1.47 Million | 75.98 Million | 61.63 Million | 4.52 Million | 125.41 Million |
| Other Financing Activities | 82.75 Million | 183 Thousand | 816 Thousand | 310 Thousand | 68.27 Million | 496 Thousand |
| Accounts receivables | 405 Thousand | 11.21 Million | 7.7 Million | -17.13 Million | 1.35 Million | 786 Thousand |
| Accounts payables | -559 Thousand | -8.68 Million | -2.67 Million | -12.97 Million | 481 Thousand | 825 Thousand |
| Inventory | - | 97 Thousand | 113 Thousand | -6.04 Million | -1.35 Million | 2.76 Million |
| Other working capital | 214 Thousand | -349 Thousand | -371 Thousand | -4.17 Million | 1.41 Million | -8.54 Million |
| Cash at beginning of period | 30.97 Million | 42.85 Million | 58.41 Million | 44.58 Million | 49.51 Million | 10.2 Million |
| Cash at end of period | 30.67 Million | 30.97 Million | 42.85 Million | 58.41 Million | 30.77 Million | 49.51 Million |
| Capital Expenditure | - | - | - | -113 Thousand | -11 Thousand | -140 Thousand |
| Effect of forex changes on cash | - | - | - | 1000.00 | - | - |
| Net cash flow / Change in cash | -301 Thousand | -11.88 Million | -15.56 Million | 13.83 Million | -18.73 Million | 39.3 Million |
| Free Cash Flow | -25.34 Million | -29.2 Million | -56.36 Million | -137.19 Million | -65.11 Million | -52.87 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.39 Million | -6.24 Million | -6.15 Million | -27.87 Million | -6.58 Million | -10.05 Million |
| Depreciation & Amortization | - | -777 Thousand | -255 Thousand | -255 Thousand | - | - |
| Deferred income taxes | - | - | 1.02 Million | -3.2 Million | - | - |
| Stock-based compensation | 885 Thousand | 985 Thousand | 710 Thousand | 3.3 Million | 863 Thousand | 876 Thousand |
| Change in working capital | 656 Thousand | -1.94 Million | 595 Thousand | 60 Thousand | 569 Thousand | -392 Thousand |
| Other non-cash items | -433 Thousand | 2.1 Million | -1.05 Million | 2.62 Million | 289 Thousand | 985 Thousand |
| Investing Cash Flow | 19.02 Million | -3.56 Million | -62.35 Million | -57.35 Million | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | -5 Million | 5 Million | - | - |
| Investment purchases | -6.88 Million | -15.16 Million | -62.35 Million | -62.35 Million | - | - |
| Sales/Maturities of investments | 25.9 Million | 11.6 Million | - | - | - | - |
| Other Investing Activities | - | - | 5 Million | 5 Million | - | - |
| Financing Cash Flow | -3000.00 | -4000.00 | 82.66 Million | 82.39 Million | -47 Thousand | -5000.00 |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | 360 Thousand | -360 Thousand | - | - |
| Common Stock Issuance | - | - | 82.66 Million | 82.75 Million | -47 Thousand | -5000.00 |
| Other Financing Activities | -3000.00 | -4000.00 | 82.76 Million | 82.75 Million | -47 Thousand | -5000.00 |
| Accounts receivables | -2.83 Million | -1.29 Million | 482 Thousand | 405 Thousand | -16 Thousand | -129 Thousand |
| Accounts payables | 3.52 Million | -612 Thousand | 993 Thousand | -559 Thousand | 77 Thousand | -1.11 Million |
| Inventory | - | - | 77 Thousand | - | -77 Thousand | - |
| Other working capital | -35 Thousand | -34 Thousand | -957 Thousand | 214 Thousand | 585 Thousand | -263 Thousand |
| Cash at beginning of period | 19.11 Million | 30.67 Million | 15.5 Million | 30.97 Million | 20.7 Million | 30.28 Million |
| Cash at end of period | 29.65 Million | 19.11 Million | 30.67 Million | 30.67 Million | 15.5 Million | 20.7 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 10.53 Million | -11.55 Million | 15.17 Million | -301 Thousand | -5.19 Million | -9.57 Million |
| Free Cash Flow | -8.48 Million | -7.98 Million | -5.13 Million | -25.34 Million | -5.15 Million | -9.57 Million |
RYLPF
MDIKF
PRENW
TDSGF
062040
2437